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Contagious bovine pleuropneumonia (CBPP) is a serious respiratory disease of cattle caused byMycoplasma mycoides subsp.
mycoides. Current vaccines against CBPP induce short-lived immunity and can cause severe postvaccine reactions. Previous
studies have identified the N terminus of the transmembrane lipoprotein Q (LppQ-N=) ofM. mycoides subsp.mycoides as the
major antigen and a possible virulence factor. We therefore immunized cattle with purified recombinant LppQ-N= formulated in
Freund’s adjuvant and challenged them withM. mycoides subsp.mycoides. Vaccinated animals showed a strong seroconversion
to LppQ, but they exhibited significantly enhanced postchallenge glomerulonephritis compared to the placebo group (P
0.021). Glomerulonephritis was characterized by features that suggested the development of antigen-antibody immune com-
plexes. Clinical signs and gross pathological scores did not significantly differ between vaccinated and placebo groups. These
findings reveal for the first time the pathogenesis of enhanced disease as a result of antibodies against LppQ during challenge and
also argue against inclusion of LppQ-N= in a future subunit vaccine for CBPP.
Contagious bovine pleuropneumonia (CBPP) is a serious respi-ratory disease of cattle characterized by coughing, fever, and
respiratory distress and causing major economic losses, particu-
larly in sub-Saharan Africa (1–3). Whereas CBPP has been con-
trolled in a number of developed countries through a combina-
tion of coordinated surveillance, eradication of whole infected
herds, and quarantine (4), these methods are not effective in de-
veloping countries due to geopolitical, economic, and cultural
considerations (3, 5, 6). Vaccination is therefore considered the
most appropriate control measure for CBPP in sub-Saharan Af-
rica. However, the most widely deployed vaccine against CBPP in
sub-Saharan Africa, as recommended by the Food and Agricul-
tural Organization (FAO), is the live attenuated Mycoplasma my-
coides subsp. mycoides vaccine strain T1/44, which induces only
short-lived immunity and causes severe postvaccine skin lesions
in a proportion of vaccinates (7). In addition, there is evidence
that that CBPP-associated lung damage has a significant immu-
nological component (8). Development of an improved vaccine
for CBPP therefore requires careful evaluation of antigen candi-
dates used for a vaccine and exclusion of those components that
induce enhancement of the disease.
Surface lipoproteins have been identified as potential trig-
gers of the massive inflammatory reaction that is caused by M.
mycoides subsp. mycoides and other mycoplasmal infections.
Whereas the role of mycoplasma lipoproteins in induction of pro-
inflammatory cytokines has been demonstrated (9, 10), data as to
the precise role of these proteins in the outcome of disease are
limited. The M. mycoides subsp. mycoides transmembrane lipo-
protein Q (LppQ) induces strong, early, and persistent antibody
responses in cattle undergoing natural CBPP infection (11). This
led to the development of a CBPP diagnostic enzyme-linked im-
munosorbent assay (ELISA) based on the membrane-exposed N-
terminal fragment of LppQ (LppQ-N=) (12). Nicholas et al. con-
ducted a preliminary study to determine the vaccine efficacy of
this determinant (13). In that study, 4 cattle were vaccinated with
recombinant LppQ-N= packaged in immunostimulating com-
plexes (ISCOMs) and boosted 6 weeks later, before being placed,
along with 4 unvaccinated control animals, in contact with cattle
that had been infected with CBPP by intrabronchial instillation.
After 4 months, 2 vaccinated animals died, coincident with an
increase in M.mycoides subsp. mycoides-specific antibody levels as
measured by competition ELISA (C-ELISA) (13) and comple-
ment fixation test (CFT). In addition, 3 out of 4 control unvacci-
nated animals died of CBPP. Postmortem observations indicated
that the LppQ-N=-vaccinated group had enhanced disease, as re-
vealed by more extensive lung lesions and fibrin deposition as well
as the presence of more abundant pleural fluid, compared to that
in the placebo group. However, despite these indications, no de-
tails on the pathological outcome in this limited number of ani-
mals were given.
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Therefore, we conducted a vaccine trial using LppQ-N= formu-
lated in Freund’s adjuvant and evaluated the clinical, pathological,
and immunological outcomes after challenge with an infective
dose of M. mycoides subsp. mycoides. Based on our observations,
we describe a novel mechanism of CBPP pathogenesis and discuss
the suitability of LppQ-N= as a vaccine candidate against CBPP.
MATERIALS AND METHODS
Expression and purification of recombinant LppQ-N=. The recombi-
nant polyhistidine-tailed 26.5-kDa N terminus of the LppQ protein was
expressed and purified from transformed Escherichia coli BL21(DE3) cells
and prepared as described previously (11). Production of the LppQ-N=
fusion protein was induced by the addition of 1 mM isopropyl--D-1-
thiogalactopyronaside (IPTG) at mid-exponential phase and incubation
for a further 3 h. Following induction, the fusion protein was purified
from cell extracts dissolved with 8 M urea using Ni2 chelate affinity
chromatography (Qiagen) according to the manufacturer’s instructions.
The bound fusion proteins were eluted at 250 mM imidazole in sodium
phosphate buffer (20 mM NaH2PO4, 0.5 M NaCl, 8 M urea, pH 8). Fol-
lowing elution, the fusion protein was dialyzed against 50 mM phosphate
buffer–300 mM NaCl (pH 7.4) and quantified using the test tube method
of the Coomassie (Bradford) protein assay kit (Pierce, Rockford, IL, USA)
as described by the manufacturer. Typically, a 100-ml culture of E. coli
yielded 2 to 4 mg of the 26-kDa LppQ-N= protein in the 200 mM imida-
zole fraction. The identity of LppQ-N= was confirmed by immunoblotting
using antihistidine monoclonal antibody (MAb) (Qiagen) and bovine
CBPP recovery serum (Fig. 1). In this blot, unpurified lysate containing
the histidine-tagged recombinant L--glycerol-3-phosphate oxidase
(rGlpO) of M.mycoides subsp. mycoides was used as an additional positive
control for LppQ-N=.
In vitro culture and quantification ofM. mycoides subsp.mycoides.
Lyophilized aliquots of the virulent M. mycoides subsp. mycoides strain
B237, which originated from an acute case of CBPP in central Kenya (14),
were reconstituted in prewarmed (37°C) Gourlay medium (15) and prop-
agated as described previously (16). M.mycoides subsp. mycoides for chal-
lenge infection was quantified on the basis of color-changing units (CCU)
per milliliter using the method of Spearman and Karber (17) as described
previously (16). M. mycoides subsp. mycoides was considered suitable for
inoculation on the third day of passage if the culture appeared filamentous
and was at pH 6.5.
Vaccination and experimental infectionof cattle.Vaccination of cat-
tle was conducted in compliance with the United Kingdom Animals (Sci-
entific) Procedures Act (1986) and was approved by the Animal Experi-
mentation Ethics Committees of both the National Veterinary Research
Center, Muguga (Nairobi, Kenya), and the Moredun Research Institute
(Scotland, United Kingdom). This was a randomized double-blind vac-
cine trial where 14 1-year-old Zebu steers from a CBPP-free zone that
tested seronegative by CFT were assigned unique identifiers and random-
ized into 2 equal groups using an MS Excel spreadsheet. One group was
inoculated subcutaneously with 200 g of recombinant LppQ-N= in 1 ml
of phosphate-buffered saline (PBS) (pH 7.4) emulsified in an equal vol-
ume of complete Freund’s adjuvant (CFA). Cattle were boosted after 4
weeks and 6 weeks with the same quantity of antigen emulsified in incom-
plete Freund’s adjuvant (IFA) (Sigma). The same number of animals in
the placebo group was similarly inoculated with 2 ml of PBS-CFA emul-
sion and boosted with PBS-IFA.
For challenge infection, cattle were sedated by subcutaneous injection
of 2 ml undiluted xylazine (Bayer AG, Leverkusen, Germany) and inocu-
lated via an endobronchial tube with 60 ml of culture (at exponential
phase and pH 6.5) containing 108 CCU/ml of M. mycoides subsp. my-
coides. This inoculum was immediately followed by 30 ml of PBS (pH 7.4)
and 15 ml of prewarmed 10% low-melting-point agar. Rectal tempera-
tures were measured daily thereafter and clinical signs monitored
throughout the period of the experiment. Animals showing continuous
fever for 10 days were euthanized on ethical grounds, while all other sur-
vivors were euthanized on the 35th day after challenge infection. All ani-
mals were bled for preparation of serum before challenge and prior to
euthanasia. During the entire period of the study, all animals were housed
together. The identity of animals in each group was kept secret until the
end of the trial. To ensure uniformity and blinding, the challenge infec-
tion and clinical monitoring were conducted by a veterinarian who did
not share information with the postmorterm pathologist.
Postmorterm lung pathological scoring. A pathology score for each
animal at postmorterm was calculated using a modification of the scoring
system described by Hudson and Turner (18). Briefly, a lesion score of 1
was assigned to a resolving lesion with only fibrous tags or pleural fibrous
adhesion lesion score, a score of 2 was added to the lesion score if myco-
plasma was isolated from the lung lesion, and the total was multiplied by
a factor determined by the diameter of the lesion (1 for5 cm, 2 for20
cm but5 cm, and 3 for20 cm). Hence, the maximum pathology score
for each animal was (2 2)3 12.
Isolation ofM. mycoides subsp.mycoides from experimental cattle.
Lung tissue from areas with lesions and those appearing grossly normal
was excised aseptically, immersed in bottles containing 50 ml prewarmed
Gourlay medium (with phenol red indicator, which turns yellow as the
medium pH changes due to bacterial metabolism or contamination with
other microbes), and incubated at 37°C in a humidified incubator with
5% CO2. The cultures were examined daily for growth and/or contami-
nation. On the third day, after change of color from red to yellow, cultures
were streaked on prewarmed tryptose agar plates (formulated as for Gour-
lay medium but containing 20 g/liter agar [Difco]), which were sealed and
incubated at 37°C for 10 days. Four dilutions (1:10, 1:20, 1:30, and 1:40) of
each broth culture were also prepared in fresh medium and examined
daily for growth. M. mycoides subsp. mycoides was considered to be pres-
ent if all dilutions of broth cultures changed from orange to yellow within
14 days and when corresponding agar plates showed mycoplasmal mor-
phological features, including the typical “fried egg” appearance charac-
teristic of M. mycoides subsp. mycoides colonies.
Immunoblotting and complement fixation test. Immunoblots were
prepared as described previously (19) with some modifications. Briefly,
proteins were transferred to a nitrocellulose (NC) membrane with a pore
size of 0.45 m (Protran Whatman Gmbh, Germany) using the Hoefer
electroblotting system (Serva Electrophoresis GmBH, Heidelberg, Ger-
FIG 1 Recombinant LppQ-N= reacts with CBPP immune sera. Immunoblots
were probed with CBPP-negative bovine serum (1:100) (A), antihistidine
MAb (1:4,000) (B) and CBPP-positive serum (1:100) (C). Arrows indicate the
rLppQ-N= molecule as well as the native protein in M. mycoides subsp. my-
coides lysate. Recombinant histidine-tagged GlpO was used as a positive con-
trol, hence causing the positive signals in panels B and C. The high background
in panel C reflects cross-reacting antibodies to E. coli proteins in unpurified
rGlpO lysate.
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many) under a constant voltage of 20 V overnight at 4°C. Membranes
were blocked with 5% bovine serum albumin (BSA) in PBS-T (Tris-buff-
ered saline, 0.05% Tween 20) for 1 h and then washed in PBS-T before
being incubated for 1 h with primary antibody diluted 1/100 in PBS-T and
then washed and incubated for 1 h with horseradish peroxidase-conju-
gated goat anti-bovine IgG (Sigma). Bands were visualized by incubation
in 30% diaminobenzidine (DAB) and 1% H2O2 in PBS until sufficient
resolution was achieved, whereupon the reaction was stopped by the ad-
dition of 1 mM HCl.
The CBPP CFT kit (CIRAD, Montpellier, France) was used to detect
antibodies against M.mycoides subsp. mycoides following challenge infec-
tion. Essentially, 25 l of test sample serum diluted in kit Veronal buffer
was distributed in 96-well round bottom plates (Costar Corning, MA,
USA) before addition of M. mycoides subsp. mycoides antigen and diluted
kit guinea pig complement. The mixture was vigorously shaken and incu-
bated with periodic shaking for 30 min at 37°C before addition of the
hemolytic system (3% sheep red blood cells [SRBC] and hyperimmune
anti-SRBC rabbit serum) and further incubation for 30 min at 37°C with
periodic shaking. The plates were then centrifuged at 125 	 g for 2 min,
and the extent of hemolysis was determined by examination over a mirror.
Test serum was considered positive for CBPP antibodies if complete in-
hibition of hemolysis was observed at a dilution of 1/10.
Processing and staining of tissues for light microscopy. Formalin-
fixed tissues were trimmed, placed in labeled cassettes, and automatically
dehydrated (Shandon Hypercenter XP system; Global Medical Instru-
mentation [GMI], Ramsey, MN, USA). The tissues were embedded in wax
using an automatic tissue processor (Triangle Biomedical Sciences Inc.,
Durham NC, USA). Four 4-m sections were cut and floated on the
surface of a preheated (45 to 55°C) water bath before transfer to a micro-
scope slide. Tissue sections were rehydrated by sequential immersion in
xylene (3 times for 3 min) and ethanol (3 times for 3 min) and 3 washes in
95% ethanol, 80% ethanol, and deionized water, respectively. Sections
were dipped in Gills hematoxylin (VWR) for 10 min before washing with
water, counterstaining with 1% eosin (VWR) for 1 min, and immersion in
1% acid ethanol. Sections were washed in ethanol and xylene and then
coverslipped using Histomount mounting solution (Vector Laboratories,
Peterbrough, United Kingdom).
Immunohistochemistry. Four 4-m sections were sequentially im-
mersed in xylene, then immediately transferred to ethanol, and finally
placed in a water bath for 15 min. Antigen retrieval was achieved by im-
mersion of sections in preheated citrate buffer (0.25% trisodium citrate
hydrate and 0.025% citric acid in deionized water, pH 6.1). The sections
were then heated in a microwave oven (800 W for 10 min), cooled in
citrate buffer, and rehydrated. Immunohistochemistry was carried out
using the Novolink polymer detection system kit (Leica Microsystems,
Newcastle, United Kingdom) according to the manufacturer’s instruc-
tions. A monoclonal antibody (MAb) raised against the membrane-lo-
cated L--glycerol-3-phosphate (GlpO) of M. mycoides subsp. mycoides
(produced in-house at the International Livestock Research Institute
[ILRI]), at the optimal dilution of 1:500, was used as primary antibody.
The sections were dehydrated and visualized after mounting with Histo-
mount (Vector).
Statistical analysis. Nonparametric tests were used to analyze out-
come variables. The two-tailed Mann-Whitney test was used to analyze
lung pathological scores and duration of fever, while Fisher’s exact test
was used to analyze kidney pathology, lung pathology (vasculitis), and
clinical signs of coughing and respiratory distress. Postchallenge survival
was analyzed by the log rank (Mantel-Cox) test. All statistical analyses
were performed using Prism version 5.04 for Windows (GraphPad Soft-
ware, San Diego, CA, USA).
RESULTS
Antibody responses. To evaluate antibody responses to LppQ-
N=, total M.mycoides subsp. mycoides lysate was probed in immu-
noblots with sera taken from individual animals before vaccina-
tion, 1 day before challenge, and on the day of euthanasia (Fig. 2).
Vaccination with rLppQ-N= induced antibodies to LppQ in all
FIG 2 Vaccination of cattle with rLppQ-N= induces antibody responses to native full-length LppQ. Top panels, LppQ-vaccinated group; bottom panels, placebo
group. For each animal, serum was taken before vaccination, 1 day before challenge, and on the day of necropsy. Each lane contains M.mycoides subsp. mycoides
total lysate reacted with bovine serum at a dilution of 1/100. Anti-LppQ reactions are revealed as a band corresponding to 48 kDa representing the full-size LppQ.
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immunized animals before challenge (Fig. 2, top panels), with a
number of apparently nonspecific determinants of various sizes
presenting with weaker signals. These weaker determinants were
also present in samples taken after challenge but prior to euthana-
sia, although the dominant response remained toward LppQ and
an additional protein of approximately 34 kDa. In the placebo
group, no specific LppQ responses were detected before or after
challenge (Fig. 2, bottom panels). We also measured complement-
fixing antibodies in sera from all animals 1 day before challenge
and on the respective day of euthanasia for each animal (Table 1).
No animal in either group showed positive CFT titers before chal-
lenge (data not shown). However, all animals tested positive for
CFT antibodies prior to euthanasia, with the exception of one
(animal 609) in the placebo group. Titers ranged from 1/10 to 1/80
and were typically higher in the vaccinated group (Table 1).
Clinical signs, gross pathological findings, and isolation of
M. mycoides subsp.mycoides. All study animals were monitored
for the following 3 key clinical signs of acute and subacute CBPP:
presence of coughing, presence of respiratory distress, and dura-
tion of fever. No statistical differences (coughing, P 1.0; respi-
ratory distress, P  0.19; median duration of fever, P  0.5) be-
tween the vaccinated and placebo groups were observed for all
these parameters.
Two cattle (28.6%) in each group survived until being eutha-
nized on the 35th day after challenge (Fig. 3A). Of these 4 survi-
vors, only one animal, from the placebo group, was found to have
CBPP lung lesions. Using the log rank (Mantel-Cox) test, there
was no significant difference between the experimental and pla-
cebo groups in the proportions that survived challenge infection
(P 0.939). Postmorterm pathological scores were determined as
described in Materials and Methods and are shown in Fig. 3B.
Pathological scores did not significantly differ (P 0.39) between
the vaccinated and placebo groups using the two-tailed Mann-
Whitney test. Lung lesions were found in five vaccinated animals
(71.4%), and in six placebo group animals (85.7%). In areas with
lesions, lung tissue was swollen (up to 2 to 3 times the original
size), edematous, and consolidated. On excision, the lesions ex-
hibited red hepatization, thickened interlobular septa, and a mar-
bled appearance. All cattle with lung lesions showed pathological
features of fibrinous bronchopneumonia with pleuritis that are
typical of acute and subacute CBPP. Most affected pleural surfaces
were covered by scanty to moderate deposits of fibrin. In all cattle
with lesions, the mediastinal lymph nodes draining the caudal
lobes were enlarged.
The most pronounced difference between the vaccinated and
placebo groups was the presence of scattered pale kidney lesions in
5 (71.4%) animals of the former group but in none of the latter
group (Fig. 4). This difference was statistically significant using
Fisher’s exact test (P  0.021). Notably, all 5 vaccinated animals
that had lung lesions also displayed kidney lesions. The pale
foci were scattered on the visceral surface and confined to the
cortex. Each lesion varied between 0.5 cm and 3.0 cm in diam-
eter (Fig. 4A).
Histological and immunohistological findings. Hematoxylin
and eosin (H&E) staining of lung lesions obtained from both the
vaccinated and placebo groups showed large irregular areas of
necrosis surrounded by large numbers of lymphocytes and neu-
trophils and occasional macrophages in a dense fibrous stroma.
Some lesions were flooded with a proteinaceous exudate and were
edematous. There was marked thickening of the interlobular
TABLE 1 Complement-fixing antibody titers to total M. mycoides
subsp. mycoides antigen in vaccinated and placebo group animals on the
respective day of euthanasia
Group Animal CFT titera
LppQ-N= 600 1/40
601 1/80
605 1/20
606 1/40
607 1/20
608 1/40
610 1/80
Placebo 602 1/20
603 1/10
604 1/10
609 0
611 1/20
612 1/10
613 1/10
a Test serum was considered positive for CBPP antibodies if complete inhibition of
hemolysis was observed at a dilution of 1/10. Values are the highest dilution at which
inhibition of hemolysis was observed.
FIG 3 Vaccination of cattle with LppQ-N= has no effect on the postchallenge
survival rate, although it seems to be associated with higher pathological
scores. (A) Survival curve displaying the rate of survival of LppQ-N=-vacci-
nated and placebo groups following challenge infection. Animals were eutha-
nized after 10 days of continuous fever or at the end of the trial (35th day after
challenge). (B) Gross pathological scores of vaccinated and placebo groups.
The combined pathological scoring focused on size and appearance of lung
lesions and isolation of M. mycoides subsp. mycoides, with a score of 12 as the
most severe and 0 as absence of lung lesion.
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septa, and alveolar walls were infiltrated with macrophages and
giant cells. Fibrinoid necrosis of blood vessel walls and intramural
and perivascular invasion with neutrophils and lymphocytes (leu-
kocytoclastic vasculitis and cuffing) were observed in 4 vaccinated
cattle that also had lung lesions (Fig. 5A and B) but were absent in
unvaccinated animals (Fig. 5C and D) except for 1. Nonetheless,
this difference was not significant using Fisher’s exact test (P 
0.26). In vaccinated cattle, immunohistochemical staining with
anti-GlpO MAb revealed a strong association between vasculitis
and presence of M. mycoides subsp. mycoides antigen around the
vascular endothelium (Fig. 5A and B).
Hematoxylin and eosin staining and immunohistochemical
staining of kidney sections are shown in Fig. 6. In kidney sections
of vaccinated cattle, widespread mesangial thickening of the glo-
merular basement membrane was observed, accompanied by
scattered small interstitial lymphoplasmacytic aggregates and ar-
eas of fibrosis around the glomerulus (Fig. 6B). In contrast, kidney
tissues from the placebo group had either no detectable abnormal-
ity or only mild mesangial thickening (Fig. 6C). Immunohisto-
chemical staining of kidney sections from vaccinated cattle with
kidney lesions revealed the presence of M. mycoides subsp. my-
coides antigen along the glomerular basement membrane (Fig.
6B). However, no M. mycoides subsp. mycoides antigen was ob-
served in unvaccinated cattle (Fig. 6D).
DISCUSSION
The transmembrane lipoprotein LppQ of M.mycoides subsp. my-
coides is known to induce strong, specific, and persistent antibody
responses in infected cattle (11), which makes it an attractive can-
didate for serological diagnosis of CBPP) (12). However, its utility
as a vaccine has been challenged by a preliminary study that re-
vealed exacerbation of disease following challenge of 4 cattle vac-
cinated with recombinant LppQ-N= formulated in ISCOMs (13).
We intended to clarify this situation by undertaking a robust eval-
uation of the responses of cattle to immunization with LppQ-N=
and the outcome of their challenge with M. mycoides subsp. my-
coides.
All animals seroconverted to LppQ following immunization,
as revealed by immunoblotting of pre- and postchallenge sera.
Interestingly, only one additional determinant, of 34 kDa, was
evident in immunoblots probed with postchallenge sera (Fig. 2, to
panels), The reasons behind this narrow response to challenge are
unclear, as is the basis of the virtual absence of a response in the
animals in the placebo group following challenge. This may reflect
the timing of sampling; both CFT and LppQ ELISA titers peak at
approximately 50 days following infection and are low to unde-
tectable at day 35 (12). It is possible that the additional reaction to
the 34 kDa antigen of the M. mycoides subsp. mycoides band seen
in the LppQ-N=-immunized cattle after challenge with M. my-
coides subsp. mycoides arose from enhanced presentation of M.
mycoides subsp. mycoides antigen as a result of opsonization of the
organism with anti-LppQ antibodies.
Since no detectable clinical changes were observed in cattle
after vaccination, it appears that LppQ-N= alone does not induce a
reaction of clinical relevance. However, postchallenge observa-
tions indicated that compared to the placebo group, the vacci-
nated group had a more severe pathological outcome, as evi-
denced by lesions of glomerulonephritis (Fig. 4A), and a tendency
toward higher pathological scores and occurrence of vasculitis,
although the latter two did not attain statistical significance. The
small number of animals in the study rendered it difficult to dem-
onstrate significant clinical and pathological differences between
vaccinated and placebo group animals, except for the statistically
significant presence of kidney lesions in the former. We believe
that an experimental study with adequate power may confirm our
observations. Considering that CBPP pathogenesis involves, at
least in part, aberrant host immune responses to the pathogen (20,
21), it is reasonable to conclude that this adverse pathological
outcome was mediated either wholly or in part by anti-LppQ-N=
antibodies and their interaction with the organism. The vasculitis
and glomerulonephritis observed in vaccinated animals are con-
sistent with immune complex disease and type 3 hypersensitivity
(Arthus reaction). An important drawback to the current study is
our inability to establish an ELISA to quantify anti-LppQ-N= an-
tibodies. Such an assay would have been useful to demonstrate
whether high antibody titers to LppQ-N= correspond with the
occurrence of immune complexes.
Histological changes observed in the lungs of both vaccinated
and unvaccinated cattle are indicative of the massive inflamma-
tion that is known to be triggered by M. mycoides subsp. mycoides
invasion (21). Unlike animals in the placebo group, the majority
of vaccinated animals showed fibrinoid necrosis of blood vessel
walls with intramural and perivascular infiltration by neutrophils,
lymphocytes, and occasional macrophages (Fig. 5A), all of which
FIG 4 Experimental infection of LppQ-N=-vaccinated cattle results in gross
kidney lesions. Photomicrographs of kidney appearance are shown. (A) LppQ-
N=-vaccinated animal 607; (B) placebo group animal 609. Note the scattered
lesions on the kidney of the vaccinated animal; the largest lesion is shown by
the arrow. The placebo group animal shows a grossly normal kidney.
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are features of vasculitis. Indeed, in addition to infiltration of the
lung parenchyma adjacent to necrotic areas in these animals, in-
flammatory lesions in the interlobular septa were centered on
blood vessels (angiocentric distribution). Further, the observed
lung lesions are likely to be a consequence of ischemia secondary
to the vasculitis.
Infectious agents have been implicated in the pathogenesis of
vasculitides in both medical (22, 23) and veterinary (24) fields. In
mycoplasma infections, vasculitis as a pathological manifestation
of disease has been reported previously for Mycoplasma pneu-
moniae (25), M. synoviae (26), M. mycoides subsp. capri (27), M.
bovis (28), and M. capricolum subsp. capripneumoniae (29). In a
study to determine the efficacy of an inactivated ISCOM vaccine
consisting mainly of M. mycoides subsp. mycoides cell membrane
proteins, Hübschle et al. (13) reported the presence of pro-
nounced vasculitis in affected lung tissue of vaccinated cattle. Sim-
ilar to the findings of the present study, vasculitis was not observed
in the unvaccinated group. Taken together, these findings suggest
that while vasculitis is a feature of M. mycoides subsp. mycoides
infections, previous exposure to LppQ-N= results in an enhanced
inflammatory reaction upon experimental infection with M. my-
coides subsp. mycoides. This is likely to be associated with the for-
mation of immune complexes, which are fundamental to the de-
velopment of vasculitis. Hence, rather than providing protection,
antibodies to LppQ-N= may accentuate the disease through en-
hancement of the vasculitis that is characteristic of infection.
The presence of lesions in the kidneys is typically observed in a
proportion of cattle infected with CBPP and has been reported in
both field (30) and experimental (31) infections. Kidney lesions
were also observed in 88 (12.2%) of 716 cattle killed after an out-
break of CBPP in 61 herds between 1990 and 1991 in Lombardy,
Italy (32). Although no attempt was made to isolate live M. my-
coides subsp. mycoides from kidneys in the present study, previous
isolation of viable M. mycoides subsp. mycoides from kidneys has
been achieved (31–33). In two of these studies, the presence of
viable M. mycoides subsp. mycoides in the kidney was frequently
associated with kidney spots (31, 32). Additionally, it has been
demonstrated that M. mycoides subsp. mycoides antigen can be
detected in the kidney, even after the clearance of viable M. my-
coides subsp. mycoides (34). In a study by Grieco et al., immuno-
histochemical analysis revealed the presence ofM.mycoides subsp.
mycoides antigen in the kidneys of 84.4% of cattle with kidney
lesions, with some lesions being surrounded by dense lymphoin-
flammatory infiltrates (32). The current data on vasculitis second-
ary to CBPP infection and vaccination suggest that the renal ne-
crosis has an ischemic basis.
The reaction in the renal cortex is consistent with deposition of
antigen-antibody complexes followed by recruitment of proin-
FIG 5 Experimental infection of LppQ-N=-vaccinated cattle results in pulmonary vasculitis that corresponds with the presence and distribution of M. mycoides
subsp. mycoides antigen. (A and C) H&E-stained sections of pulmonary blood vessels from vaccinated animal 605 (A) and placebo group animal 609 (C). Dense
perivascular invasion by lymphocytes and occasional macrophages is evident in the section from animal 605 and is marked by an arrow. Magnification,	300.
(B and D) IHC staining for M.mycoides subsp. mycoides antigen in pulmonary blood vessels from vaccinated animal 608 (B) and placebo group animal 603 (D).
The arrow in panel B shows M. mycoides subsp. mycoides antigen concentrated around the vascular endothelium. M. mycoides subsp. mycoides antigen is not
present in the endothelium of animal 603. Magnification,	300.
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flammatory cells to affected areas. The thickening of the glomer-
ular basement membrane and the formation of adhesions to the
Bowman’s capsule are consistent with immune complex-medi-
ated glomerulonephritis. The pathogenesis of this condition in-
volves penetration of immune complexes across the vascular en-
dothelium but not the basement membrane, resulting in
deposition on the endothelial surface. Alternatively, immune
complexes may accumulate in the mesangial region of the glom-
eruli and manifest grossly as thickening of the mesangial basement
membrane. Further support for immune complex deposition is
given by Grieco et al. (32), who, in acute CBPP infections, ob-
served antigen in the glomeruli as forming a curvilinear pattern in
the capillary tuft when immunolabeled. This pattern is consistent
with immune complex deposition (35). The lymphocytic aggre-
gates observed in the present case were also observed by Grieco et
al. (32) and may arise from the ability of the tubular epithelial cells
to act as antigen-presenting cells since they can express major
histocompatibility complex (MHC) class II molecules on their
surfaces (36).
The observations in the current study have strong parallels
with those for another bacterial disease in which an adverse out-
come has been observed following vaccination and challenge (37,
38). Van den Bosch and Frey (38) reported that vaccination of pigs
with PalA, an outer membrane protein of Actinobacillus pleuro-
pneumoniae, the agent of porcine pleuropneumonia, resulted in
enhanced disease rather than protection after experimental infec-
tion. In that study, three pigs were vaccinated intramuscularly and
boosted with recombinant PalA before challenge with A. pleuro-
pneumoniae aerosol. All three died from the challenge infection,
with only one death observed in the control group. Significantly,
when PalA was mixed with two other antigens with an established
history of protection, the beneficial effects of these antigens was
lost. The mechanism for this exacerbated disease in vaccinated
pigs remains unclear. Nonetheless, pleural inflammation in por-
cine pleuropneumonia closely resembles that of CBPP, and it is
tempting to speculate that vaccination of cattle with LppQ-N=
precipitates a reaction similar to that observed with PalA in pigs.
Any similarities in the enhanced disease induced by prior expo-
sure to PalA and LppQ remain to be determined.
Aside from subunit vaccine experiments, CBPP vaccine re-
search has focused mainly on either live attenuated M. mycoides
subsp. mycoides (7, 39, 40) or inactivated formulations of M. my-
coides subsp. mycoides surface or total antigens (41–43). In gen-
eral, the results of these studies suggest that inactivated or whole
M. mycoides subsp. mycoides cell lysates induce poor protection,
although Gray et al. (42) claimed to have achieved complete pro-
tection against natural infection by vaccination with an extreme
regimen involving two immunizations with massive doses of M.
mycoides subsp. mycoides lysate formulated in complete Freund’s
adjuvant. While a variety of factors could be responsible for the
poor protection induced by these formulations, the results of the
current study suggest that determinants such as LppQ-N= may
FIG 6 Experimental infection of LppQ-N=-vaccinated cattle results in glomerulonephritis that is associated with the presence of M. mycoides subsp. mycoides
antigen. (A and C) H&E-stained sections of glomeruli. (A) The glomerular basement of vaccinated animal 605 is thickened (arrow), and scattered lymphocytic
aggregates can be seen in the interstitium. (C) These changes are absent in the glomerulus of placebo group animal 611. Magnification,	350. (B and D) IHC
staining for M.mycoides subsp. mycoides antigen in glomeruli. (B) Glomerulus of vaccinated animal 608, showing M.mycoides subsp. mycoides antigen along the
glomerular basement membrane (arrow). (D) Glomerulus of placebo group animal 611 without M. mycoides subsp. mycoides antigen.
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prime the immune system for potentially harmful responses that
are recalled by challenge. The findings of Gray et al. (42) are sig-
nificant in that massive doses of M. mycoides subsp. mycoides ly-
sate appear to be capable of inducing total protection. This sug-
gests that one or more M.mycoides subsp. mycoides antigens in the
lysate induced protective mechanisms that overcame the negative
responses provoked by antigens such as LppQ-N=. Therefore, the
challenge for CBPP vaccine development remains the identifica-
tion of antigens that induce the desired protective response. As
more antigens are identified and tested for protective capacity, it
will be important to demonstrate that they induce protective im-
mune responses rather than predisposing cattle to exacerbated
disease.
We have described exacerbation of CBPP pathology following
subunit vaccination and subsequent experimental infection with
M.mycoides subsp. mycoides and have provided evidence that this
exacerbation is associated with immune complex formation.
Thus, vaccination of cattle with recombinant LppQ-N= and exper-
imental challenge with live infective M. mycoides subsp. mycoides
resulted in more severe disease that was characterized by vasculitis
and glomerulonephritis, both of which are strongly suggestive of
immune complex disease. Whereas immune complex disease
seems to be a feature of both natural and experimental CBPP, our
results indicate that previous exposure to LppQ-N= enhances this
pathological mechanism. These findings support a case for the
omission of LppQ-N= in future vaccines against CBPP and, per-
haps, its orthologues in vaccines for other mycoplasma infections.
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